Biotech investors don’t lose money because they can’t read a pipeline.
They lose money because they overreact to the wrong numbers.
In a sector where a single trial update can reprice an entire company overnight, it’s tempting to anchor on the loudest …

Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System (Explained)
In pharma, “protection” isn’t one thing—it’s a stack.
A lot of people think the story is simple: a patent expires, generics arrive, and the market resets. Bu…

First-to-File, First-to-Profit: The Hidden Math Behind Paragraph IV and 180-Day Exclusivity
In generic drug competition, timing isn’t just strategy—it’s economics.
A single filing can determine whether a generic manufacturer earns meaningful market sha…

Generic and biosimilar launches don’t fail because the science is wrong. They fail because the timing is.
For years, formulary teams have treated “loss of exclusivity” as a calendar event: once the patent wall comes down, the generic or biosimilar shou…

Pharma doesn’t publish its future. It publishes its past.
That’s the uncomfortable truth behind most “pipeline” conversations—and why competitive forecasting is getting rewritten by pharmaceutical patent intelligence.
In the traditional model, compan…

20 Years on Paper: The Real Guide to Drug Patent Duration in the United States
For anyone in pharma—whether you’re a founder, investor, in-house counsel, or BD leader—“20 years” is the number everyone quotes.
But in practice, the real timeline for drug…

Pick the right patent—or leave billions on the table.
In pharma, the difference between winning and losing isn’t always the science. It’s the paperwork. The strategy. The timing.
A single misstep in patent selection can quietly turn a carefully bui…

South America’s drug patent map is no longer a “nice-to-know.” It’s a competitive advantage.
If you’re a pharma executive, investor, or IP strategist, you’ve probably felt the same frustration: one headline about a granted patent here, a vague note abo…

Combining Lipitor (atorvastatin) with aspirin has been a topic of interest for healthcare professionals due to their common… https://www.Drugchatter.com/chat/18474/what-are-the-effects-of-combining-lipitor-and-aspirin/